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A largemajority of thyroid nodules are benign, and only
5%havemalignant features on cytological examination.
Unfortunately, fine-needle aspiration is inconclusive in
approximately 30% of all thyroid biopsies, because the
cytological features are indeterminate (suspicious for
malignancy but not completely diagnostic or nondiag-
nostic). Wide panels of somatic mutations have been
identified in thyroid cancers, and detection of genetic
alterations in fine-needle aspirate has been demon-
strated to improve diagnostic accuracy. Nevertheless,
the relatively high number of genetic targets to be
investigated, in comparison with the low percentage
of malignant samples, makes the usual diagnostic
protocol both time-consuming and expensive. We de-
veloped a reliable and sensitive protocol based on
high-resolution melting analysis for the rapid screen-
ing of mutations of KRAS, HRAS, NRAS, and BRAF
oncogenes in thyroid fine-needle aspirations. The en-
tire procedure can be completed in approximately 48
hours, with a dramatic reduction in costs. The pro-
posed protocol was applied to the analysis of 260
consecutive fine-needle aspiration biopsy (FNAB)
samples. In 35 of 252 samples, 36 sequence variants
were detected for BRAF (17 samples), NRAS (6 sam-
ples), HRAS (3 samples), KRAS codon 12 (9 samples),
and KRAS codon 61 (1 sample). (J Mol Diagn 2012, 14:
501–509; http://dx.doi.org/10.1016/j.jmoldx.2012.03.003)
Thyroid cancer is the most common malignancy of the
endocrine system, accounting for approximately 1% of all
malignancies in Western countries.1 The incidence of
thyroid cancer has increased 2.6-fold in the last 30 years.
This change is attributed not only to an increment in
papillary thyroid carcinoma,2 but also to more wisely con-
ducted medical surveillance and improvements in diag-
nostic tools.3 The large majority of thyroid nodules, as
discovered with the use of new diagnostic imaging tech-niques, are asymptomatic and benign. In this context,
diagnostic studies are becoming essential to identify the
small fraction of thyroid nodules that harbor malignant dis-
ease and to predict when surgery is indicated. Fine-needle
aspiration biopsy (FNAB) has emerged over the past 30
years as an accurate and cost-effective procedure for the
preoperative screening of thyroid nodules, representing the
gold standard for differential diagnosis of benign and ma-
lignant nodules.4 Under recent guidelines,5,6 cytological
smears are classified in five categories for the diagnostic
report: Thy 1, nondiagnostic; Thy 2, benign or negative for
malignant cells; Thy 3, all follicular lesions (including atypia/
follicular lesion of undetermined significance and follicular
neoplasm or suspicious for follicular neoplasm); Thy 4, sus-
picious; and Thy 5, diagnostic for malignancy.
Although the overall accuracy of FNAB is considered
excellent, approximately 30% of cytological aspirates do
not allow definitive diagnosis of malignancy, because of
intrinsic and unavoidable characteristics of samples.7 The
major limitations of FNAB procedures are linked to inade-
quate and indeterminate specimens and, in that sense, are
also linked respectively to the nondiagnostic or follicular
lesions categories.8,9 Thus, a clinical need emerges for the
characterization of aspirates with suspicious features but
with unsatisfactory cellularity, to allow accurate distinction of
benign from malignant forms of follicular lesions.
Several somatic mutations have been identified in thy-
roid cancer, stimulating the search for genetic alterations
in FNAB that could increase the diagnostic accuracy of
traditional cytology. Numerous studies have demon-
strated that identification of specific mutations in cytolog-
ical specimens can assist in the diagnosis by FNAB and
in the clinical decision to excise the nodule and to inten-
sify the follow-up.10–16 In most cases, genetic alterations
are represented by activating mutations of oncogenes
that are mutually exclusive and linked to distinct histolog-
ical subtypes, with a demonstrated pathogenic role in
thyroid cell transformation as effectors of the RAS/RAF/
MAPK signaling cascade.
The presence of BRAF mutations, a frequent alteration
in papillary carcinoma (PTC), evolves into an unregulated
activation of the intracellular MAPK pathway that can
promote tumorigenesis and tumor progression. The main
mutation of BRAF, identified exclusively in PTC, affects
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JMD September 2012, Vol. 14, No. 5nucleotide 1799 in exon 15 and results in thymine-to-
adenine transversion, which translates into valine-to-glu-
tamate substitution at residue 600 (p.V600E).17 The ad-
jacent p.K601E mutation has rarely been identified,18 and
no mutation in exon 11 has been described in thyroid
cancers. BRAF mutations are associated with poor clini-
cal prognosis due to extrathyroid invasion and higher risk
of relapse and metastasis.19
Mutations in the family of RAS oncogenes, which encode
for G-proteins that also convey signals to the MAPK path-
way, are more common in follicular carcinomas (FTC)20 and
in follicular variant of papillary carcinoma (fvPTC).21 Point
mutations in the HRAS, KRAS, and NRAS genes are asso-
ciated with specific domains of the protein and are able
either to increase its affinity for substrate (substitution in
residues 12 and 13) or to inactivate the autocatalytic
GTPase function (residue 61). RAS mutations seem to be
related to benign as well as malignant growth of nodules;
however, it is becoming evident that alterations in this family
of oncogenes are competent to lead toward anomalous
cellular transformation, through mechanisms of genomic
instability22,23 and promotion of additional mutations.24
Because of the frequency and clinical relevance of
BRAFmutations in thyroid papillary carcinomas (45% of
all cases) and RAS mutations in follicular subtypes (40%
to 50% of these tumors),25 the detection of these genetic
alterations in FNABs has been widely adopted, to increase
the specificity of testing. Development of rapid and accu-
rate molecular methods could therefore be important for the
screening of the large number of samples routinely col-
lected by FNAB, to obtain a molecular diagnosis in a time
frame compatible with clinical decision-making.
High-resolution melting (HRM) analysis is a technique
recently developed for mutation scanning of PCR prod-
ucts.26–29 The discrimination between wild-type and vari-
ant sequences is obtained by the comparison of the
dissociation shape of amplicons when exposed to in-
creasing temperature. A change in melting profile, gen-
erated by signal of fluorescent dyes intercalating only
double-stranded DNA, is caused by a variation in the
sequence, relative to the reference sample.30
Our aim in the present study was to assess an inex-
pensive HRM analysis platform for the accurate analysis
of a consistent number of cytological samples. The prin-
cipal objectives were the optimization of an accurate test
for a rapid screening of mutation-positive thyroid nodules
and the evaluation of a molecular marker panel to refine




Nodule biopsies were obtained from 260 consecutive
patients [53 men and 207 women; mean age, 55.1 years
(range, 21–80 years)] undergoing FNAB for suspicious
thyroid nodules. Eight samples out of the series, resulted
negative at thyroglobulin assay, were excluded from sub-
sequent molecular analysis.FNABs were performed under ultrasound guidance
using a 21- to 23-gauge needle by performing five or six
passes. FNAB was performed on all single nodules with a
diameter 5 mm. In 13 patients with multiple nodules,
FNAB was performed on a maximum of two dominant
nodules for each patient. One biopsy was performed for
each nodule. All samples to be submitted to cytopathol-
ogy analysis were processed according to thin-layer cy-
tology technique, as described previously.31 The widest
diameter of all nodules ranged from 6 to 75 mm (23.8 
11.0, mean  SD).
The sample obtained from biopsies was used for
classical cytology and the needle washing was used
for molecular assay. Fifty patients randomly selected
underwent a second FNAB, which was used for molec-
ular analysis (on both tissue and needle washing). All
FNAB samples were collected in a single tube contain-
ing 500 L of RNAlater stabilizing reagent (Qiagen,
Milan, Italy). After one night at 4°C, samples were
stored at 80°C until extraction of nucleic acids. The
study was approved by the local ethics committee.
Informed consent had been obtained previously from
all patients.
DNA and RNA Purification from FNAB and
Control Cell Line Selection
Cytological material was centrifuged at 15,890  g for 15
minutes, and then the buffer was removed without dis-
turbing the pellet. Immediately, 700 L of RLT lysis buffer
from an RNeasy micro kit (Qiagen) was added to the
samples. Resuspended samples were divided into two
350-L aliquots, one for DNA and one for RNA extraction.
DNA was extracted using a Qiagen QIAamp DNA micro
kit according to manufacturer’s protocol for isolation of
genomic DNA from tissue. Similarly, RNA was extracted
using a Qiagen RNeasy micro kit according to the man-
ufacturer’s protocol for purification of total RNA from an-
imal and human tissues. The entire RNA sample was
reverse-transcribed using MuLV Reverse Transcriptase
(Applied Biosystems-Life Technologies, Foster City, CA)
and random hexamer primers in a final volume of 40 L.
Before testing for chromosomal rearrangements, 2.5 L
of cDNA was evaluated for GAPDH, using Applied Bio-
systems TaqMan control reagents, and for thyroglobulin
gene expression (TaqMan gene expression assays;
Hs00794359_m1, NM_003235.4). RNA from the human
papillary thyroid carcinoma cell line TPC1 and from the
human prostatic carcinoma cell line PC3 was used as
positive and negative control, respectively, for thyroglob-
ulin expression.
For investigation of DNA point mutations, positive
controls were obtained from cell lines harboring se-
quence variation in the target genes. DNA from the
human T-cell lymphoblast-like cell line CCRF-CEM and
the human colorectal adenocarcinoma cell line SW948
was selected as reference for the KRAS codon 12
(p.G12D, heterozygous) and 61 (p.Q61R, heterozy-
gous) variants, respectively. CCRF-CEM was also used
as a control for HRAS (p.A59A, heterozygous). DNA
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was used as mutated reference for the NRAS codon 61
variant (p.Q61R, heterozygous). Finally, a reconsti-
tuted sample of human skin melanoma cell line SK-
MEL-28 (BRAF p.V600E, homozygous) mixed with hu-
man breast cancer cell line MCF-7 DNA (wild-type
BRAF) was used as heterozygous reference for exon
15 BRAF gene. HT1197, MCF-7, SK-MEL28 cell lines
were supplied by Banca Biologica e Cell Factory
(IRCCS Azienda Ospedaliera Universitaria San Martino –
IST Istituto Nazionale per la Ricerca sul Cancro). More-
over, CCRF-CEM and SW948 cell lines were provided
by ATCC-LGC Standards Partnership. DNA was ex-
tracted from all cell lines using a QIAamp DNA mini kit
(Qiagen).
Amplification Conditions for DNA Mutation
Screening
The primer sets covering the hot-spot sites of genes were
as listed in Table 1. During primer design (Primer3Plus
software; http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi), the acceptable annealing temperature
was set to be identical among different pairs and the
product size was considered optimal within a range of
150 to 200 bp. Each amplicon was tested to exclude
amplification of sequence homolog regions [UCSC Ge-
nome Browser applications In-Silico PCR (http://genome.
ucsc.edu/cgi-bin/hgPcr?orgHuman&dbhg19&hgsid
285213467) and BLAT Search (http://www.genome.ucsc.
edu/cgi-bin/hgBlat?commandstart)]. PCR reactions were
performed in an ABI 2720 thermal cycler (Applied Biosys-
tems-Life Technologies) using 10 ng DNA in a total volume
of 20 L containing a final concentration of 1 PCR buffer
II (10 mmol/L Tris-HCl, pH 8.3; 50 mmol/L KCl) (Applied
Biosystems-Life Technologies), 1.5 mmol/L MgCl2
solution, 0.2 mmol/L each dNTP, 0.5 mol/L each primer,
0.5 mol/L SYTO 9 green fluorescent nucleic acid stain
(Invitrogen-Life Technologies, Carlsbad, CA), and 1 U
AmpliTaq Gold DNA polymerase (Applied Biosystems-
Life Technologies). Cycling conditions entailed an initial
denaturation at 95°C for 10 minutes, followed by 45 cy-
cles at 95°C for 20 seconds, 58°C for 30 seconds, and
72°C for 30 seconds, with a final elongation step at 72°C
Table 1. Primer Sets and Conditions for Hot Spots of Interest in
Gene Codon Sequence
BRAF 600–601 Fwd: 5=-TGCTTGCTCTGATAGGAAAAT
Rev: 5=-CCACAAAATGGATCCAGACA-
HRAS 61 Fwd: 5=-ATGGCAAACACACACAGGAA-
Rev: 5=-GATTCCTACCGGAAGCAGGT-
NRAS 61 Fwd: 5=-CCCCTTACCCTCCACACC-3=
Rev: 5=-TGGCAAATACACAGAGGAAGC
KRAS 12–13 Fwd: 5=-GTCACATTTTCATTATTTTTA
Rev: 5=-TTTACCTCTATTGTTGGATCA
KRAS 61 Fwd: 5=-ACTGTGTTTCTCCCTTCTCAG
Rev: 5=-ATGGCAAATACACAAAGAAAG
*Annealing temperature was consistently 58°C.for 20 minutes.HRM Analysis
The DNA from FNAB samples was screened by HRM
analysis in a RotorGene 6000 system (Qiagen, Hilden,
Germany). The denatured samples, obtained by an initial
hold of 3 minutes at 95°C and 3 minutes at 40°C, were
analyzed by the acquisition of fluorescence signal in a
temperature range experimentally determined for each
tested gene (Table 1). The melting ramp was set at 0.08
degrees/each step for each assay. All samples were run
in duplicate.
DNA Sequencing
To confirm HRM analysis results, sequencing analysis
was also performed in all samples. After HRM, samples
were purified with a PCR purification kit (Qiagen) and
submitted to cycle sequencing with 2 L of BigDye
Terminator ready reaction mix (Applied Biosystems-
Life Technologies) and the same primers used in PCR
at a final concentration of 0.16 mol/L in a volume of 20
L. After purification with a DyeEx 2.0 spin kit (Qiagen),
samples were analyzed with an ABI Prism 310 genetic
analyzer (Applied Biosystems-Life Technologies).
Amplification Conditions for Chromosomal
Rearrangement Screening
The screening of chromosomal rearrangements (RET/
PTC1, RET/PTC3, and PAX8/PPARG) was developed us-
ing primer sets reported by Nikiforov et al.16 Amplification
reactions were performed in simplex assay on a 7900HT
fast real-time PCR system (Applied Biosystems-Life
Technologies) using 2.5 L of cDNA in a total volume of
12.5 L containing a final concentration of 1 QuantiTect
SYBR Green from a PCR kit (Qiagen) and 300 nmol/L of
each primer. PCR was performed as follows: an initial
hold at 95°C for 15 minutes, followed by 45 two-step
cycles at 95°C for 15 seconds and 60°C for 60 seconds.
The amplification products of chromosomal rearrange-
ments assays were submitted to melting analysis to con-
firm the specificity of the fluorescence signal obtained
during the amplification of cDNA. The thermal profile
consisted of a denaturing/annealing stage (95°C for 15
seconds, 60°C for 15 seconds), followed by a dissocia-
nalysis of Thyroid Nodules















C-3=tion stage from 60°C to 95°C (ramp rate, 2%).
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Quality of Nucleic Acids
The quality of nucleic acids purified from 260 cytological
biopsies indicated that the collection procedure and the
extraction systems were suitable for development of mu-
tation screening. In fact, it was possible to amplify by
PCR all the DNA samples, as well as the RNA reverse-
transcribed into cDNA extracted from the related biopsy.
The performance of RNA extraction was verified by the
amplification of the control gene, GAPDH; thyroglobulin
expression was evaluated with a thyroid-specific marker
to confirm the presence of thyroid cells in the FNAB
specimens. Only eight samples out of the series (3%)
were negative for thyroglobulin assay and therefore un-
reliable for molecular testing. Five of the eight samples
had been classified as inadequate biopsies during the
previous cytological diagnosis.
Mutation Scanning by HRM Analysis and
Sequencing
The HRM analysis, set up by using DNAs from cell lines,
was useful in the recognition of DNA mutations along all
hot-spot regions investigated (Figure 1). Screening the
Figure 1. HRM analysis of cell lines harboring mutations in BRAF, KRAS (co
cell lines used as reference during prescreening of FNAB sample. Results
homozygous) mixed with MCF-7 (BRAF wild type) (top left); DNA from C
SW948 for KRAS codon 61 (p.Q61R, heterozygous) (top right); and DNA fro
and from HT1197 as mutated reference for NRAS codon 61 (p.Q61R, heterozygous)
indicated by an arrow.FNAB samples provided a satisfactory resolution of melt-
ing for all of the DNA sites of interest and allowed the
amplification of all genes simultaneously.
To evaluate the theoretical sensitivity of our method, a
detection limit was calculated, as described previously,29
by using serial dilution of positive controls (cell lines
CCRF-CEM, SW948, HT1197, SK-MEL28) in wild-type
DNA (from MCF-7 cell line) for each gene under study.
We were able to detect the presence of mutated DNA up
to 5% in a background of wild-type DNA (data not
shown).
Examples of HRM profiles for mutated samples and
corresponding sequencing results, obtained after HRM
analysis, are shown in Figure 2. The dideoxy-sequencing
always confirmed HRM genotyping of mutated samples,
including those cases in which the electropherogram
demonstrated a faint peak corresponding to a mutated
allele.
Mutated FNABs, Cytological Categories, and
Histopathology
Using a simple and rapid application of HRM analysis, we
identified 38 mutations in a total of 37 nodules. Number
and type of the genetic variants divided on the basis of
and 61), HRAS, and NRAS, with HRM profiles and melting curves of control
wn for a sample reconstituted from DNA of SK-MEL-28 (BRAF p.V600E,
M analyzed for KRAS codon 12 (p.G12D, heterozygous) (top middle) and
F-CEM used as heterozygous control for HRAS gene (p.A59A) (bottom left)dons 12
are sho
CRF-CE
m CCR(bottom right). The mutated reference sample for the gene of interest is
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JMD September 2012, Vol. 14, No. 5Figure 2. Examples of hot-spot mutations detected by HRM in FNAB samples. The mutated sample identified by HRM assay is indicated by an arrow.
Electropherograms (top right in each panel) confirm the presence of a mutation in the sample with different melting behavior; the nucleotide affected by mutation
is bordered by a dotted box. For HRAS and KRAS, mutations caused by different nucleotide substitutions that are clearly detectable by HRM.
d KRAS
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ported in Tables 2 and 3, respectively. Only one sample
simultaneously carried mutations in two different genes
(BRAF p.V600E and KRAS p.G12D). The BRAFV600E mu-
tation was confirmed as the most frequent alteration in
FNAB samples, particularly in the cytological categories
of suspicious (Thy 4) and malignant nodules (Thy 5), with
a frequency of 44.4% and 100%, respectively. In NRAS,
only the most recurrent p.Q61R was identified, in a total of
six samples (three Thy 2 and three Thy 3) (Table 2).
Conversely, mutations caused by different nucleotide
substitutions were detected by HRM analysis in the HRAS
and KRAS genes (HRAS p.Q61R and p.Q61K; KRAS
p.G12R and p.G12D) (Figure 2). Nodules positive for a
mutation in RAS genes varied in distribution across cyto-
logical categories and were more frequently found in
indeterminate specimens (Thy 3, with a frequency of
16.7%). Within the Thy 3 category, the BRAF p.V600E
mutation was detected in two samples (Table 2), both of
which were classified histologically as PTC.
In two cases the analysis by HRM analysis and se-
quencing identified unusual in tandem mutations in
KRAS, caused by the substitution of adjacent nucleotides
(Figure 3) and resulting in the presence of both a synony-
mous and a missense mutation: KRAS p.[G60G()Q61K]
and p.[G12G()G13R]. Similar mutations have been de-
scribed previously in colorectal cancer,32 but never in thy-
roid FNAB samples, nor in thyroid carcinoma.
Last, during chromosomal rearrangement investiga-
tion, we found three samples characterized by the pres-
ence of RET/PTC rearrangement (2 RET/PTC1 and 1 RET/
PTC3; Table 2).
Histopathology results were available for a total of 56
patients (Table 3). In addition to the expected concor-
dance in the Thy 4 and Thy 5 groups, molecular diagno-
Table 2. Genetic Variants Identified by HRM Analysis of Thyroid
Thy 1 [no. (%)] Thy 2 [no. (%)] T
Total sample 31 (12.3) 154 (61.1)
Samples with mutation 4 (12.9) 8 (5.2)
BRAF (codon 600–601) 0 1
NRAS (codon 61) 0 3
HRAS (codon 61) 0 1
KRAS (codon 12–13) 3 2
KRAS (codon 61) 0 0
RET/PTC 1 1
One sample carried two mutations simultaneously (BRAF p.V600E an






Thy 2 154 4
Thy 3 48 38
Thy 4 9 9
Thy 5 10 5sis in the Thy 3 category identified 5/9 (55%) patients with
mutations among the histologically positive samples and
26/29 (90%) patients without mutations (wild-type DNA)
among histologically negative samples.
Discussion
In recent years, both research and clinical management
of thyroid cancer have been deeply modified and revised
on the basis of genetic features of the tumor. Involvement
of independent pathways in the carcinogenesis of thyroid
cancer is supported by the great variability in the pattern
of somatic mutations.33 In a parallel fashion, the number
of patients requiring clinical evaluation of thyroid nodules
has dramatically increased. Even if FNAB is considered
an accurate preoperative test to distinguish benign
from malignant thyroid nodules, cytological examina-
tion is inconclusive in approximately 30% of all thyroid
nodule biopsies7,34 classed as indeterminate (Thy 3,
follicular lesion of undetermined significance or sam-
ples suspected for follicular neoplasm) or nondiagnos-
tic (Thy 1, insufficient cells). These patients are typi-
cally subjected to surgery, to exclude a thyroid cancer
diagnosis. Approximately 20%of patients with FNABbiopsy
showing indeterminate cytological features have thyroid
cancer revealed on histological examination and may re-
quire a complete thyroidectomy.12 Typical genetic altera-
tions are described for most differentiated thyroid cancers,
which constitute approximately 90% of all cases.25 In clini-
cal management, given the importance of a correct classi-
fication of cytologically undefined FNAB, rapid and accu-
rate methods are needed to screen the most common
somatic mutations in a series of known oncogenes.
les, by Cytological Category
o. (%)] Thy 4 [no. (%)] Thy 5 [no. (%)] All samples [no. (%)]
9.0) 9 (3.6) 10 (4.0) 252 (100)
2.9) 5 (55.6) 10 (100.0) 38 (15.1)
4 10 17 (6.7)
0 0 6 (2.4)
1 0 3 (1.2)
0 1 9 (3.6)
0 0 1 (0.4)
0 0 3 (1.2)
p.G12D).
les, by Histological Findings
Histology
indings (no.)
Mutations in related cytological
sample (no.)
1 positive 1 BRAF
3 negative 1 RAS; 2 wild type
9 positive 2 BRAF; 2 RAS; 1 RET/PTC; 4 wild type
29 negative 3 RAS; 26 wild type
8 positive 4 BRAF; 1 RAS
1 negative 1 wild type
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ples harboring mutations, irrespective of the substitution
type. Thus, HRM could be considered a valid prescreen-
ing method to analyze, through a single methodological
approach, a large sample in a short time and to make an
accurate characterization of several molecular markers
that are affected by many types of mutations. This capa-
bility is clearly confirmed for different types of nucleotide
changes, both in the case of first-class substitutions such
as G/A and C/T, which are easily detectable, and in the
case of the fourth-class A/T change, which is generally
more difficult to discriminate. In addition, the use of an
amplicon-based melting method with saturating dyes al-
lows the detection of non-hot-spot sequence variants30
with potential clinical value that would not be identifiable
with allele-specific techniques. In the present study, we
identified two samples carrying rare KRAS variants pre-
viously described in colorectal cancer but not in thyroid
cancer. Thus, HRM analysis provides a reliable, cost-
limited, and accurate approach to rapid genetic screen-
ing. Because specific mutated allele detection is not the
crucial point in FNAB thyroid samples, comparison
among different methods should be based mainly on the
basis of test practicability, costs, and turnaround time of
sample evaluation.
Most of the available assay methods used for FNAB
molecular characterization produce similar results in
terms of sensitivity and specificity. As reported by Jin et
Figure 3. Examples of rare variants detected by HRM in FNAB samples. The
profiles of two samples (indicated by arrows), compared with wild-type sa
substitutions.al35 for BRAF p.V600E mutation, the choice of four differ-ent approaches (direct sequencing, the colorimetric
TrimGen Mutector assay, PCR with FRET probes, and
PCR with SYBR Green) does not significantly affect the
molecular diagnosis, and the choice of the best test de-
pends mainly on the laboratory expertise and available
financial and technical resources.
In addition, the present HRM-based technique provides
levels of sensitivity higher than direct sequencing. In a pre-
vious study29 on colorectal cancer, we demonstrated the
high sensitivity of HRM analysis, which allowed identifying
at least 5% of mutated alleles in a background of wild-type
DNA. Even though HRM analysis has been widely applied
for the screening of somatic variants in biopsies of solid
cancers, only a few previous applications of HRM analysis
have been reported in the screening of cytological material,
as fixed fresh cells36 or scraped cells from archival slides37
obtained from needle aspiration.
The main objective in the present study was to develop
a reliable and sensitive test for the rapid screening of
mutations in KRAS, HRAS, NRAS, and BRAF oncogenes
in thyroid FNAB. Within the proposed protocol, we can
provide results of the complete screening of FNAB sam-
ples in approximately 48 hours. This result was obtained
by optimization of PCR protocols, based on the simulta-
neous amplification of the different targets at the same
primer annealing temperature. After amplification, each
tube is immediately submitted to HRM. In the presence of
an abnormal melting profile, the same amplification prod-
e of a double mutation in KRAS is easily identified from the abnormal melting
In electropherograms, arrows indicate the nucleotides affected by adjacentpresencuct can be immediately submitted to direct sequencing,
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negative for any of the oncogene mutations included in
our panel are immediately submitted to quantitative real-
time PCR and for detection of thyroglobulin mRNA and
chromosomal rearrangements. The presence of mRNA
for thyroglobulin indicates the effective presence of thy-
roid-derived nucleic acids in the sample and precludes
false negative results.
As already noted, the entire procedure can be com-
pleted in a reduced time interval without affecting reliabil-
ity of the results. The other relevant consequence of our
protocol is a dramatic reduction of costs. First of all, HRM
is a post-PCR step that does not require significant fur-
ther costs (the addition of intercalating dye, for example,
can be quantified in €0.006 per tube). Furthermore, the
execution of direct sequencing limited only to samples
that yielded abnormal melting profiles reduced by more
than 80% the costs connected to the entire process for
sequence analysis.
The optimization of the proposed procedure guaran-
tees high levels of sensitivity, because we obtained cor-
rect amplification in all FNAB samples, as well as in those
samples for which only needle washing was available. In
this particular application, the low amount of starting bi-
ological sample available from FNAB washing and the
consequent need for a highly sensitive method to obtain
accurate results, especially in the case of multiple as-
says, has to be taken into account. On the other hand, the
definition of test reliability and sensitivity as percentage of
mutated allele is highly relevant for the evaluation of the
analytical performance of a diagnostic assay method.
This sensitivity precludes taking a second biopsy only to
collect tissue for molecular testing.
In the present study, we detected sequence variants of
the proposed oncogenes in approximately 15% of all
samples, a percentage similar to that reported by oth-
ers.10,12 Moreover, we detected 10/48 mutated samples
(21%) with a higher incidence of RAS variants in compar-
ison with previous reports in Thy 3 patients.10,16
In addition to establishing the evident advantages of
HRM prescreening in terms of time and economic im-
provement, this pilot study confirmed the accuracy of the
proposed method. Complete concordance was found
between the standard protocol, based on sequencing of
all samples, and the HRM-based screening.
Acknowledgments
We thank Angela Magini, Gabriele Parenti, Antonio Cilotti,
and Giovanni Cantelli for their clinical contributions.
References
1. Sherman SI: Thyroid carcinoma. Lancet 2003, 361:501–511
2. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM: Analysis of
the rising incidence of thyroid cancer using the Surveillance, Epide-
miology and End Results national cancer data registry. Surgery 2010,
148:1147–11523. Davies L, Welch HG: Increasing incidence of thyroid cancer in the
United States, 1973–2002. JAMA 2006, 295:2164–21674. Tallini G, Gallo C: Fine-needle aspiration and intraoperative consul-
tation in thyroid pathology: when and how? Int J Surg Pathol 2011,
19:141–144
5. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, Vitti
P; AACE/AME/ETA Task Force on Thyroid Nodules: American Asso-
ciation of Clinical Endocrinologists, Associazione Medici Endocri-
nologi, and European Thyroid Association medical guidelines for
clinical practice for the diagnosis and management of thyroid nod-
ules. Endocr Pract 2010, 16 Suppl 1:1–43
6. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid
Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM,
Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B,
Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Re-
vised American Thyroid Association management guidelines for pa-
tients with thyroid nodules and differentiated thyroid cancer [Erratum
appeared in Thyroid 2010, 20:674–675]. Thyroid 2009, 19:1167–
1214
7. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY, Hwang
TS: Pyrosequencing analysis for detection of a BRAFV600E mutation
in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008,
17:118–125
8. Gharib H, Papini E: Thyroid nodules: clinical importance, assessment,
and treatment. Endocrinol Metab Clin North Am 2007, 36:707–735, vi
9. Layfield LJ, Cibas ES, Gharib H, Mandel SJ: Thyroid aspiration
cytology: current status. CA Cancer J Clin 2009, 59:99–110
10. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G,
Toti P, Di SantoA, Caruso G, Carli AF, Brilli L, Montanaro A, Pacini F:
Impact of proto-oncogene mutation detection in cytological speci-
mens from thyroid nodules improves the diagnostic accuracy of
cytology. J Clin Endocrinol Metab 2010, 95:1365–1369
11. Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP,
Seethala RR, Carty SE, Ogilvie JB, Yip L, Nikiforov YE: Contribution of
molecular testing to thyroid fine-needle aspiration cytology of “follic-
ular lesion of undetermined significance/atypia of undetermined sig-
nificance”. Cancer Cytopathol 2010, 118:17–23
12. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh
QY, Clark OH, Kebebew E: Molecular testing for somatic mutations
improves the accuracy of thyroid fine-needle aspiration biopsy. World
J Surg 2010, 34:2589–2594
13. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi
R, Cavazzini L, Roti E, degli Uberti EC: BRAF V600E mutation analysis
increases diagnostic accuracy for papillary thyroid carcinoma in fine-
needle aspiration biopsies. Eur J Endocrinol 2009, 161:467–473
14. Shibru D, Chung KW, Kebebew E: Recent developments in the clin-
ical application of thyroid cancer biomarkers. Curr Opin Oncol 2008,
20:13–18
15. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau
SO, Hodak SP, Ogilvie JB, Nikiforov YE: Optimizing surgical treatment
of papillary thyroid carcinoma associated with BRAF mutation. Sur-
gery 2009, 146:1215–1223
16. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper
JP, Zhu Z,Fagin JA, Falciglia M, Weber K, Nikiforova MN: Molecular
testing for mutations in improving the fine-needle aspiration diagnosis
of thyroid nodules. J Clin Endocrinol Metab 2009, 94:2092–2098
17. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA:
High prevalence of BRAF mutations in thyroid cancer: genetic evidence
for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway
in papillary thyroid carcinoma. Cancer Res 2003, 63:1454–1457
18. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo
V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A,
Cameselle-Teijeiro J, Sobrinho-Simões M: Type and prevalence of
BRAF mutations are closely associated with papillary thyroid carci-
noma histotype and patients’ age but not with tumour aggressive-
ness. Virchows Arch 2005, 446:589–595
19. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda
M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R:
BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Endocr Relat Cancer 2008, 15:191–205
20. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco
C: Specific pattern of RAS oncogene mutations in follicular thyroid
tumors. J Clin Endocrinol Metab 2003, 88:2745–2752
21. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE: Molecular
profile and clinical-pathologic features of the follicular variant of pap-
HRM for Thyroid Nodule Screening 509
JMD September 2012, Vol. 14, No. 5illary thyroid carcinoma. An unusually high prevalence of ras
mutations. Am J Clin Pathol 2003, 120:71–77
22. Fagin JA: Minireview: branded from the start-distinct oncogenic initi-
ating events may determine tumor fate in the thyroid. Mol Endocrinol
2002, 16:903–911
23. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R,
Stambrook PJ, Fagin JA: The RAS oncogene induces genomic insta-
bility in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000,
19:3948–3954
24. Finney RE, Bishop JM: Predisposition to neoplastic transformation
caused by gene replacement of H-ras1. Science 1993, 260:1524–1527
25. Nikiforova MN, Nikiforov YE: Molecular genetics of thyroid cancer:
implications for diagnosis, treatment and prognosis. Expert Rev Mol
Diagn 2008, 8:83–95
26. Margraf RL, Mao R, Highsmith WE, Holtegaard LM, Wittwer CT: RET
proto-oncogene genotyping using unlabeled probes, the masking
technique, and amplicon high-resolution melting analysis. J Mol Di-
agn 2007, 9:184–196
27. Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ; Australian
Ovarian Cancer Study Group, DeFazio A, Fox SB, Brenton JD, Bowtell
DD, Dobrovic A: High resolution melting for mutation scanning of
TP53 exons 5–8. BMC Cancer 2007, 7:168
28. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi
U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta
K, Tamura T: Epidermal growth factor receptor mutation detection
using high-resolution melting analysis predicts outcomes in patients
with advanced non small cell lung cancer treated with gefitinib. Clin
Cancer Res 2007, 13:5385–5390
29. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili
S, Mini E, Pazzagli M, Orlando C: High-resolution melting analysis forrapid detection of KRAS, BRAF, and PIK3CA gene mutations in
colorectal cancer. Am J Clin Pathol 2008, 130:247–253
30. Reed GH, Kent JO, Wittwer CT: High-resolution DNA melting analysis
for simple and efficient molecular diagnostics. Pharmacogenomics
2007, 8:597–608
31. Petrone L Petrone L, Mannucci E, De Feo ML, Parenti G, Biagini C,
Panconesi R, Vezzosi V, Bianchi S, Boddi V, Di Medio L, Pupilli C,
Forti G: A simple us score for the identification of candidates to fine
needle aspiration of thyroid nodules. J Endocrinol Invest 2011 doi:
10.3275/7978 [Epub ahead of print]
32. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS: Fre-
quency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Genes Chromosomes Cancer 2011, 50:307–312
33. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto
A, Lima J, Soares P: Intragenic mutations in thyroid cancer. Endocri-
nol Metab Clin North Am 2008, 37:333–362, viii
34. Haugen BR, Woodmansee WW, McDermott MT: Towards improving
the utility of fine-needle aspiration biopsy for the diagnosis of thyroid
tumours. Clin Endocrinol (Oxf) 2002, 56:281–290
35. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson
MR, Lloyd RV: BRAF mutation analysis in fine needle aspiration (FNA)
cytology of the thyroid. Diagn Mol Pathol 2006, 15:136–143
36. Fassina A, Gazziero A, Zardo D, Corradin M, Aldighieri E, Rossi GP:
Detection of EGFR and KRAS mutations on trans-thoracic needle
aspiration of lung nodules by high resolution melting analysis. J Clin
Pathol 2009, 62:1096–1102
37. Nomoto K, Tsuta K, Takano T, Fukui T, Fukui T, Yokozawa K, Saka-
moto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y,
Matsuno Y: Detection of EGFR mutations in archived cytologic spec-
imens of non-small cell lung cancer using high-resolution melting
analysis. Am J Clin Pathol 2006, 126:608–615
